PVX 7
Alternative Names: HPV16/18; pBI-11; pBI-11 plasmid DNA; pBI-11/TA-HPV; PVX-7Latest Information Update: 23 Jan 2024
At a glance
- Originator PAPIVAX
- Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Human papillomavirus infections
Most Recent Events
- 18 Jan 2024 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins plans a phase II trial in Human papillomavirus infections (Intradermal, IM) in January 2024 (NCT06210854)
- 16 May 2023 Phase-II clinical trials in Human papillomavirus infections (Metastatic disease, Combination therapy, Recurrent, Late-stage disease, First-line therapy) in USA (IM) (NCT05799144)
- 14 Apr 2023 PapiVax Biotech in collaboration with Vanderbilt University Medical Center (VUMC) plans a phase II trial for Human papillomavirus infections (Metastatic disease, Recurrent, Late-stage disease, First-line therapy) in USA (IM) (NCT05799144)